ZEPBOUND KWIKPEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZEPBOUND KWIKPEN (ZEPBOUND KWIKPEN).
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It binds to and activates both GIP and GLP-1 receptors, leading to increased insulin secretion in a glucose-dependent manner, decreased glucagon secretion, delayed gastric emptying, and reduced appetite, thereby improving glycemic control and promoting weight loss.
| Metabolism | Tirzepatide is metabolized via proteolytic cleavage of the peptide backbone, beta-oxidation of the fatty diacid moiety, and amide hydrolysis. It is not significantly metabolized by CYP450 enzymes. |
| Excretion | Primarily renal and fecal following proteolytic degradation; intact peptide not detected in urine. Approximately 80% of total drug-related material is excreted in urine (mostly inactive metabolites) and 20% in feces (predominantly parent drug). |
| Half-life | Terminal elimination half-life is approximately 5 days (120 hours), supporting once-weekly subcutaneous dosing. Steady-state concentrations are achieved after 4 weeks of dosing. |
| Protein binding | Tirzepatide is >99% bound to plasma proteins, primarily to albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.6 L/kg, indicating distribution primarily in extracellular fluid and not extensive tissue binding. |
| Bioavailability | Subcutaneous: Absolute bioavailability is approximately 80% after abdominal injection. |
| Onset of Action | Subcutaneous: Onset of glucose-lowering effect within 2–3 hours post-dose; peak effect on gastric emptying occurs at 4–6 hours. |
| Duration of Action | Duration of clinical effect (glycemic control and weight loss) is approximately 1 week, consistent with once-weekly administration. Effects on gastric emptying persist for at least 24 hours post-dose. |
| Molecular Weight | 4114.5 |
Subcutaneous injection once weekly. Initial dose: 2.5 mg for 4 weeks; then increase to 5 mg for at least 4 weeks; further increments of 2.5 mg every 4 weeks as tolerated up to maximum 15 mg once weekly.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment (eGFR ≥15 mL/min/1.73m²). Not studied in end-stage renal disease (eGFR <15 mL/min/1.73m²) or dialysis; use not recommended. |
| Liver impairment | No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use not recommended. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment recommended based on age alone. Consider renal function and comorbidities; monitor for adverse effects such as gastrointestinal intolerance and volume depletion. |
| 1st trimester | Teratogenic effects observed in animal studies; avoid use during first trimester due to potential for fetal harm. |
| 2nd trimester | Limited human data; consider risk vs. benefit. May cause fetal harm based on animal studies. |
| 3rd trimester | Not recommended due to potential for neonatal hypoglycemia and other adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for ZEPBOUND KWIKPEN (ZEPBOUND KWIKPEN).
| Placental transfer | Expected to cross the placenta due to molecular weight and protein binding; animal studies confirm transfer. |
| Breastfeeding | Not recommended during breastfeeding. Unknown if excreted in human milk; potential for serious adverse reactions in nursing infants. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Personal or family history of medullary thyroid carcinomaMultiple Endocrine Neoplasia syndrome type 2 (MEN-2)Hypersensitivity to tirzepatide or any product components
| Precautions | Risk of thyroid C-cell tumors (medullary thyroid carcinoma); advise patients of this risk and monitor for thyroid neoplasms, Acute pancreatitis: Discontinue if suspected; monitor for signs and symptoms, Hypoglycemia, particularly when used with insulin or insulin secretagogues; may require dose adjustment of concomitant antidiabetic therapy, Acute kidney injury: Monitor in patients with renal impairment or dehydration, Severe gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea) may lead to dehydration; consider discontinuation if intolerable, Diabetic retinopathy complications: Rapid improvement in glycemic control has been associated with worsening of retinopathy; monitor, Gallbladder disease (cholelithiasis, cholecystitis): Reported; consider if symptoms occur, Do not use in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 |
| Food/Dietary |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | FDA Pregnancy Category N (not assigned). Animal studies with tirzepatide, the active ingredient, show embryo-fetal mortality and structural abnormalities at maternal exposures below the maximum human dose. First trimester exposure may be associated with increased risk of miscarriage and congenital malformations, though human data are insufficient. Second and third trimester exposure is associated with fetal growth restriction and possible adverse metabolic effects due to the GLP-1 receptor agonism. |
| Fetal Monitoring | Monitor fetal growth with serial ultrasound due to risk of fetal growth restriction. Monitor maternal glucose control and weight. Evaluate for signs of pancreatitis and thyroid C-cell tumors. If exposure occurs during pregnancy, consider fetal thyroid monitoring given animal findings. |
| Fertility Effects | In animal studies, tirzepatide caused disruption of estrous cycles and decreased fertility at clinically relevant exposures. In humans, weight loss and improved metabolic control may improve fertility in obese patients with polycystic ovary syndrome, but the direct drug effect on fertility is unknown. |
| No specific food restrictions. However, because tirzepatide delays gastric emptying, high-fat or large meals may worsen gastrointestinal side effects (nausea, vomiting, bloating). Advise patients to eat smaller, low-fat meals and avoid fried or greasy foods to improve tolerability. Alcohol may increase risk of pancreatitis and hypoglycemia; limit intake. No grapefruit interaction known. |
| Clinical Pearls | Zepbound (tirzepatide) is a once-weekly subcutaneous injection for chronic weight management. It is a GIP and GLP-1 receptor agonist. Dose titration is required to minimize GI side effects; start at 2.5 mg weekly for 4 weeks, then increase to 5 mg. Maximum dose is 15 mg weekly. Administer any time of day with or without meals. Rotate injection sites (abdomen, thigh, upper arm). Monitor for pancreatitis, gallbladder disease, hypoglycemia (especially with insulin/secretagogues), and thyroid C-cell tumors (contraindicated if personal/family history of MTC or MEN2). Avoid in patients with severe GI disease (gastroparesis). Not studied in pregnancy; discontinue at least 2 months before planned pregnancy. |
| Patient Advice | Inject under the skin of your belly, thigh, or upper arm once a week on the same day each week. · Store the KwikPen in the refrigerator before first use; after first use, store at room temperature up to 30°C for up to 21 days. · Common side effects include nausea, vomiting, diarrhea, constipation, and stomach pain; these often improve over time. · Take your missed dose as soon as possible within 4 days; if more than 4 days have passed, skip the missed dose and resume your regular schedule. · Each pen contains 4 doses; after use, dispose of the pen in a sharps container. · Do not share your pen with others, even if the needle is changed. · Tell your healthcare provider if you have severe stomach pain, persistent nausea/vomiting, or symptoms of pancreatitis (severe pain spreading to your back). · Seek emergency medical help if you experience signs of an allergic reaction (rash, itching, difficulty breathing) or thyroid tumor (lump in neck, hoarseness, trouble swallowing). · If you take insulin or a sulfonylurea, monitor blood sugar for hypoglycemia; your dose may need to be adjusted. · Use effective contraception during treatment and for at least 2 months after stopping if you could become pregnant. |